Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer

NANJING, China, May 29, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Dr. Peng Wang, Chief Scientific Officer of the Company, effective from May 29, 2013. Dr. Wang resigned for personal reasons. His resignation has been approved by the Company.

Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We thank Dr. Wang for his contribution to our research and development efforts and we wish him all the best in the future."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases, and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857

In the United States:

Cindy Zheng

Brunswick Group LLC

Tel: 1-212-333-3810

 

In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600


SOURCE Simcere Pharmaceutical Group



RELATED LINKS
http://www.simcere.com

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.